Successful Treatment of Unresectable BRCA1 L63-Mutated Basal Cell Carcinoma Invading the Parietal Bone with Cisplatin and Fluorouracil: A Case Report

Abstract Introduction: Basal cell carcinoma (BCC) is a common skin cancer that rarely metastasizes but can deeply infiltrate local tissues. The small number of unresectable BCC cases makes it difficult to conduct clinical trials, resulting in delays in the development of effective drugs for BCC. Can...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2024-09, Vol.17 (1), p.1050-1054
Main Authors: Yoshida-Akai, Saaya, Fujimura, Taku, Amagai, Ryo, Kambayashi, Yumi, Hashimoto, Akira, Terui, Hitoshi, Oka, Kenta, Watanabe-Takahashi, Manami, Yamazaki, Emi, Ohuchi, Kota, Asano, Yoshihide
Format: Article
Language:English
Subjects:
brca1 l63
Cancer therapies
Case Report
Case reports
cisplacin
Clinical trials
Disease control
Genes
Medical imaging
Melanoma
Mutation
Patients
Skin cancer
unresectable basal cell carcinoma
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction: Basal cell carcinoma (BCC) is a common skin cancer that rarely metastasizes but can deeply infiltrate local tissues. The small number of unresectable BCC cases makes it difficult to conduct clinical trials, resulting in delays in the development of effective drugs for BCC. Cancer gene panel testing has led to an increasing number of new treatment proposals for patients with solid tumors for whom no standard treatment is available. Case Presentation: We described a case of unresectable BRCA1 L63*-mutated BCC invading the parietal bone, which was successfully treated with cisplatin and fluorouracil. Conclusion: Our present case suggests that comprehensive mutation analysis by gene panel testing is important in advanced BCC because genes other than those involved in the hedgehog signaling pathway can be driver genes.
ISSN:1662-6575
1662-6575
DOI:10.1159/000541160